OKUR director granted 4,125 fully vested RSUs on 09/30/2025
Rhea-AI Filing Summary
Edward T. Mathers, a director of OnKure Therapeutics, Inc. (OKUR), acquired 4,125 fully vested restricted stock units (RSUs) on 09/30/2025 in lieu of a quarterly cash retainer under the company's Outside Director Compensation Policy. Each RSU converts into one share of Class A Common Stock. After the reported transaction, the reporting person beneficially owns 11,399 shares. The Form 4 was filed as a single reporting-person filing and bears a signature by an attorney-in-fact dated 10/02/2025.
Positive
- 4,125 RSUs were granted and are fully vested, converting 1:1 to shares
- RSU grant was issued in lieu of a quarterly cash retainer, showing compensation alignment with equity
- Reporting person’s beneficial ownership increased to 11,399 shares
Negative
- None.
Insights
Director compensation converted to equity increases alignment with shareholders.
The filing shows 4,125 RSUs granted to Edward T. Mathers on 09/30/2025, issued in lieu of a cash retainer. Because the RSUs are fully vested and convert 1:1 into Class A Common Stock, the grant immediately increases the director's equity stake to 11,399 shares.
This is a routine disclosures for Section 16 filers and signals use of equity-based pay for outside directors rather than cash for that quarter.
Award represents a quarterly director retainer paid as equity, not a performance grant.
The Explanation states the RSUs were granted "in lieu of a quarterly cash retainer," indicating this is compensation substitution rather than a new long-term incentive award. The RSUs are fully vested, so there are no vesting contingencies disclosed that would delay conversion into shares.